Market Overview

UPDATE: Goldman Sachs Raises PT to $170 on Regeneron Pharmaceuticals on Eylea EU Approval

Share:
Related REGN
CEOs Vs. Hedge Fund Managers: Who Gets Paid Better?
Has A Biotech Recovery Started Yet?
Best Performing Nasdaq 100 Stocks (Seeking Alpha)

Goldman Sachs reiterated its Buy rating on Regeneron Pharmaceuticals (NASDAQ: REGN) and increased its price target from $168 to $170.

Goldman Sachs noted, "FDA approved REGN's Eylea for a new eye disease indication (central retinal vein occlusion, CRVO), in line with our expectation. Eylea was approved last year for the wet AMD indication. We model 2013 US Eylea sales of $1.2bn (62% yoy growth) of which CRVO contributes $104mn."

Regeneron Pharmaceuticals closed at $145.09 on Friday.

Latest Ratings for REGN

DateFirmActionFromTo
Apr 2016Wells FargoDowngradesOutperformMarket Perform
Apr 2016Leerink SwannMaintainsOutperform
Apr 2016Roth CapitalMaintainsBuy

View More Analyst Ratings for REGN
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (REGN)

View Comments and Join the Discussion!